Peptide
Bronchogen
SaveA Khavinson bioregulator tripeptide (Ala-Glu-Asp) purported to support bronchial and lung tissue function.
Quick verdict
Part of the Khavinson bioregulator series from Russian research. Published evidence is limited to small Russian-language studies.
Evidence score
12/ 100
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Primarily Russian-language publications from the Khavinson group. No international peer-reviewed RCTs.
Benefits
- Claimed respiratory tissue support in Russian literature
- Oral bioregulator peptide format
Dosage notes
Russian protocols suggest 5–10 mg/day orally in capsule form for 10–30 day courses.
Side effects
- Not well characterized
- Possible GI discomfort
Who should be cautious
Not approved outside Russia. Quality control of commercially available products is uncertain.
What this page cannot tell you
Evidence base is very narrow and not independently replicated.
Leaderboard scores
- Immunity15
Write a review
Sign in to write a review.